RECURSION PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.79 USD | -7.37% |
|
-13.44% | -20.99% |
| Mar. 15 | Recursion Pharmaceuticals Insider Sold Shares Worth $537,190, According to a Recent SEC Filing | MT |
| Mar. 11 | Recursion Pharmaceuticals to Open London Office | MT |
Chart calendar Recursion Pharmaceuticals, Inc.
c55d1558812e5118c39570de1fe.eopY2hdfVAjKJCdslJsJLDIcjQfwuG05f4dCHkgAlho.AOEBu3ltZDGgE2Mf7fpFYQdxvHGT_CENK-0QajBM-XcC_QG9USpsXJlTcg~1dcd84e9bddff548e7ac20f47d6e4795
Upcoming events on Recursion Pharmaceuticals, Inc.
Past events on Recursion Pharmaceuticals, Inc.
| 2024-04-08 10:15 am | Needham Healthcare Conference |
| 2024-03-18 | KeyBanc Life Sciences & MedTech Forum |
| 2024-03-11 02:00 pm | Leerink Partners Global Biopharma Conference |
| 2024-03-05 02:00 pm | KeyBanc Emerging Technology Summit |
| 2024-03-04 04:25 pm | Morgan Stanley Technology, Media & Telecom Conference |
| 2024-02-27 05:00 pm | Q4 2023 Earnings Call |
| 2024-02-27 04:05 pm | Q4 2023 Earnings Release |
| 2024-01-16 09:30 am | Needham Growth Conference |
| 2024-01-08 10:30 am | JPMorgan Healthcare Conference |
| 2023-11-14 03:00 am | Jefferies London Healthcare Conference |
| 2023-11-09 07:58 am | Q3 2023 Earnings Release |
| 2023-09-27 09:30 am | Goldman Sachs Global Sustainability Forum |
| 2023-09-26 11:05 am | Cantor Global Healthcare Conference |
| 2023-09-08 09:00 am | Citi Global Technology Conference |
| 2023-09-07 07:15 am | Citi BioPharma Conference |
| 2023-08-08 11:30 am | KeyBanc Technology Leadership Forum |
| 2023-08-08 07:58 am | Q2 2023 Earnings Release |
| 2023-06-28 | Morgan Stanley Biotechnology AI Summit |
| 2023-06-16 02:00 pm | Annual General Meeting |
| 2023-06-13 04:20 pm | Goldman Sachs Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 3,96 | 10,2 12,4 -17.66% | 39,8 51,2 -22.25% | 44,6 52,1 -14.47% | 53,9 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -174 -175 0.11% | -234 -256 8.74% | -326 -307 -6% | -409 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -183 -174 -4.89% | -246 -227 -8.46% | -350 -342 -2.41% | -425 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | -186 -163 -14.4% | -239 -216 -11.13% | -332 -329 -0.81% | -438 |
|
Net income Million USD | Released Forecast Spread | -87,0 | -186 -177 -5.45% | -239 -226 -6.11% | -328 -333 1.49% | -411 |
|
EPS USD | Released Forecast Spread | -5,99 | -1,49 -1,20 -24.25% | -1,36 -1,39 2.44% | -1,58 -1,66 5.01% | -1,70 |
| Announcement Date | 03/03/21 | 23/03/22 | 27/02/23 | 27/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,53 6,07 -58.25% | 5,33 84,0 -93.65% | 7,67 5,40 42.11% | 13,2 6,85 92.12% | 13,7 24,0 -43.02% | 12,1 13,2 -7.75% | 11,0 11,9 -7.54% | 10,5 12,9 -18.16% | 10,9 20,4 -46.49% | 13,1 | 13,6 | 14,2 | 14,2 | 13,5 |
|
EBITDA Million USD | Released Forecast Spread | -59,6 -75,0 20.55% | -66,1 -113 41.21% | -76,2 -63,7 -19.58% | -91,4 -85,5 -6.87% | -91,3 | -91,3 | -89,8 | -185 | -201 | |||||
|
EBIT Million USD | Released Forecast Spread | -65,0 -48,5 -33.94% | -56,0 -52,0 -7.66% | -66,2 -65,6 -0.92% | -62,6 -66,9 6.5% | -61,0 -49,8 -22.52% | -69,9 -63,0 -10.89% | -81,7 -73,1 -11.82% | -99,6 -81,9 -21.57% | -98,9 -87,9 -12.52% | -100 | -102 | -103 | -134 | -155 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -64,9 -43,0 -51.01% | -65,6 -57,0 -15.02% | -60,4 -61,0 0.91% | -57,5 -13,0 -342.25% | -65,3 -62,0 -5.37% | -76,7 -69,0 -11.2% | -93,0 -82,0 -13.44% | -94,6 -94,4 -0.24% | -106 | -106 | -108 | -117 | ||
|
Net income Million USD | Released Forecast Spread | -64,9 -50,0 -29.87% | -56,0 87,3 -164.12% | -65,6 -60,6 -8.27% | -60,4 -63,1 4.21% | -57,5 -45,9 -25.25% | -65,3 -60,2 -8.48% | -76,7 -70,6 -8.62% | -93,0 -77,5 -20.01% | -93,0 -96,7 3.87% | -98,9 | -99,4 | -99,7 | -126 | -155 |
|
EPS USD | Released Forecast Spread | -0,38 -0,30 -28.26% | -0,33 0,51 -164.71% | -0,38 -0,35 -10.1% | -0,35 -0,36 3.22% | -0,30 -0,25 -20% | -0,34 -0,34 -0.43% | -0,38 -0,37 -3.55% | -0,43 -0,38 -12.99% | -0,42 -0,45 6.69% | -0,42 | -0,41 | -0,41 | -0,48 | -0,68 |
| Announcement Date | 23/03/22 | 10/05/22 | 09/08/22 | 08/11/22 | 27/02/23 | 08/05/23 | 08/08/23 | 09/11/23 | 27/02/24 | - | - | - | - | - |
More events
Past sector events for Recursion Pharmaceuticals, Inc.
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ACELYRIN, INC.: Q4 2023 Earnings Release |
| 2024-03-28 04:02 pm | IMMUNOME, INC.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- RXRX Stock
- Calendar Recursion Pharmaceuticals, Inc.
